Drug Profile
Research programme: RNA-based therapeutics - Arrakis Therapeutics
Latest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator Arrakis Therapeutics
- Class Antineoplastics; Neuroprotectants; Small molecules
- Mechanism of Action RNA modulators; RNA splicing modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Inborn genetic disorders; Neurological disorders
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for research development in Cancer in USA
- 28 Dec 2023 No recent reports of development identified for research development in Inborn genetic disorders in USA
- 28 Dec 2023 No recent reports of development identified for research development in Neurological-disorders in USA